Interactive Therapeutics utilizes the PepZin GI brand of Zinc-Carnosine. This proprietary crystalline chelate compound outperforms traditional non-molecular combinations because it breaks down more slowly, offering the healing benefits for a longer period of time. It supports a healthy gastrointestinal system including stabilizing the mucosal lining, supporting the proper balance of gastric microbes, aids with intestinal permeability, and offers relief from mild discomfort including:
- Heartburn and GERD
- Nausea and queasiness
Zinc-Carnosine aids in the support of the stomach and intestinal lining without interfering with the body’s natural digestive process. It has been part of well over 100 studies and 38 clinical trials. The results suggest it facilitates the modulation of H. pylori along with promoting healing. It is quickly dissolved and absorbed in the stomach, however, it dissociates slowly. This allows the relief it provides to last longer.1-28
Compatible with many dietary requirements, Interactive Therapeutics Zinc-Carnosine is:
- Wheat free
- Gluten free
- Corn free
- Soy free
- Dairy free
Serving Size: 1 vegetarian capsule
Servings Per Container: 60
Amount Per Serving
Zinc-Carnosine (PepZin GI® brand)
Other Ingredients: cellulose, vegetable capsule (modified cellulose), calcium laurate, and silicon dioxide.
This product contains NO: artificail coloring, artificial flavoring, corn, dairy products, gluten, ingredients of animal origin, preservatives, salt, soy, sugar, wheat, or yeast. This product contains natural ingredients; color variations are normal.
PepZin GI® is a registered trademark of Hamari Chemicals, LTD
Dosage and Use:
- Take 1 capsule twice daily, or as recommended by your healthcare professional.
- If pregnant, nursing, or undergoing treatment for a medical condition, consult your physician before taking this product
- Keep out of reach of children
- Do not exceed recommended dose
1 Matsukura, T; Takahashi, T; Nishimura, Y; Ohtani, T; Sawada, M; Shibata, K: Chem. Pharm. Bull. (1990), 38(11), 3140-6.
2 Matsukura, T.; Tanaka, H: Biochemistry (Moscow) (2000), 65(7), 817-823.
3 Walsh, CT; Sandstead, HH; Prasad, AS; Newberne, PM; Fraker, PJ: Environ. Health Perspect (1994), 102 Suppl 2, 5-46.
4 Yamakawa, A: Showa Igakkai Zasshi. (1975), 35(2), 113-126.
5 Cho, CH: Drug Dev. Res. (1989), 17(3), 185-197.
6 Yoshikawa, T; Naito, Y; Tanigawa, T; Yoneta, T; Kondo, M: Biochim. Biophys. Acta (1991), 1115(1), 15-22.
7 Cho, CH; Luk, CT; Ogle, CW: Life Sci. (1991), 49(23), PL189-PL194.
8 Arakawa, T; Satoh, H; Nakamura, A; Nebiki, H; Fukuda, T; Sakuma, H; Nakamura, H; Ishikawa, M; Seiki, M; Kobayashi, K: Dig. Dis. Sci. (1990), 35(5), 559-66.
9 Seiki, M; Aida, H; Ueki, S; Yoneta, T; Takemasa, T; Hori, Y; Morita, H; Chaki, K; Tagashira, E: Nippon Yakurigaku Zasshi (1992), 100(2), 165-72.
10 Sunairi, M; Tanaka, N; Kuwayama, H; Nakajima, M: Yakuri to Chiryo (1994), 22(9), 3771-3775.
11 Seiki, M; Aida, H; Mera, Y; Arai, K; Toyama, S; Furuta, S; Morita, H; Hori, Y; Yoneta, T; Tagashira, E: Nippon Yakurigaku Zasshi (1992), 99(4), 255-63.
12 Matsuda, K; Mera, Y; Wada, H; Aruga, H; Saik, Y; Taniguchi, Y: Arzneim. Forsch. (1991), 41(10), 1036-1041.
13 Miyoshi A, et al. Clinical evaluation of Z-103 on gastric ulcer – a multicenter double-blind comparative study with cetraxate hydrochloride. Jpn PharmTher 1992;20(1):199-223.
14 Sugiyama T; Tanaka H; Kawai S: Journal of Bone and Mineral Metabolism (2000), 18(6), 335-338.
15 Ikui, A; Ikeda M; Yoshikawa T; Kudo I; Onoda K; Kida A: Jibiinkou (1999), 92(7), 801-804.
16 Takagi, H; Nagamine, T; Abe, T; Takayama, H; Sato, K; Otsuka, T; Kakizaki, S; Hashimoto, Y; Matsumoto, T; Kojima, A; Takezawa, J: Suzuki K; Sato S; Mori M. Journal of Viral Hepatitis (2001) 8(5) 367-71.
17 Takeda, S; Yoshikawa, T; Morita, Y; Yoshida, N; Kondo, M: J. Clin. Biochem. Nutr. (1999), 26(3), 213-225.
18 Tameyasu, T; Yamada, M; Tanaka, M; Takahashi, S: Japanese Journal of Physiology (2002), 52, 111-120.
19 Yoshikawa, T; Yamaguchi, T; Yoshida, N; Yamamoto, H; Kitazumi, S; Takahashi, S; Naito, Y; Kondo, M: Digestion (1997), 58(5), 464-468.
20 Watanabe, S; Wang, XE; Yoneta, T; Seto, K; Sato, N: Gastroenterology (1997), 112, 327A.
21 Katayama, S; Nishizawa, K; Hirano, M; Yamamura, S; Momose, Y: J. Pharm. Pharm. Sci. (2000), 3(1), 114-117.
22 Nishimura, Y; Yamagishi, Y; Ando, K; Saito, T; Matsukura, T: Biomed. Res. Trace Elem. (2001), 12(2), 159-167.
23 Boldyrev, AA; Gallant, SC; Suhkich, GT: Biosci. Rep. (1999), 19 (6), 581-7.
24 Misawa T, et al. Clinical study of Z-103 – clinical effects on gastric ulcer and influence on endocrine function. Jpn PharmTher 1992; 20(1):245-254.
25 Kuwayama H, et al. Polaprezinc. Nippon Rinsho 2002 Feb; 60 Suppl 2:717-720.
26 Hiraishi H, et al. Polaprezinc protects gastric mucosal cells from noxious agents through antioxidant properties in vitro. Aliment Pharmacl Ther 1999;13:261-269.
27 Kato S, Nishiwaki H, et al. Mucosal ulcerogenic action of monochloramine in rat stomachs: effects of polaprezinc and sucralfate. Dig Dis Sci 1997;42(10):2156-2163.
28 Naito Y, et al. Effects of polaprezinc on lipid peroxidation, neutrophil accumulation, and TNF-alpha expression in rats with aspirin-induced gastric mucosal injury. Dig Dis Sci 2001;46(4):845-851.
* These statements have not been evaluated by the Food and Drug Administration. This Product is not intended to diagnose, treat, cure or prevent any disease.